Cancer
Indication |
Patent Group |
Description |
Countries |
| Cancer |
ALL-ALA | This case relates to αLactalbumin complexes that have been engineered to optimize production | DE, DK, FI, FR, UK, NL, SE, AU, CA, IN, JP, USA |
| Cancer |
Alpha1 and Alpha2 fragment complexes | This case relates to the αLA fragment complexes – comprising the human Alpha1 or Alpha2 sequences. | CH, DE, DK, ES, FI, FR, UK, HU, IE, IT, NL, NO, PL, SE |
| USA | |||
| USA divisional | |||
| Cancer |
PAPILLOMA | This case relates to αLA complexes (including HAMLET and BAMLET) for treatment of skin papillomas. | USA |
| USA divisional | |||
| Cancer |
PROPHYLACTIC THERAPY | This case relates to αLA complexes for prophylactic treatment of cancer. | CH, DE, DK, ES, FI, FR, UK, HU, IE, IT, NL, NO, PL, SE, |
| US divisional | |||
| Cancer | NUTRACEUTICAL | This case relates to milk-based nutraceuticals that contain αLA-complexes. | CH, DE, DK, ES, FI, FR, UK, IE, IT, NL, NO, SE, USA, HK |
| Cancer | 39-MER COMPLEX | This case relates to milk-based nutraceuticals | CH, DE, DK, ES, FI, FR, UK, IE, IT, NL, NO, PL, SE, HK, AU, CA, CN, IN, JP, KP, SG, USA |
| Cancer |
MIXING METHOD | This case relates to a simplified production method. | Europe divisional |
| Hong Kong | |||
| USA continuation | |||
| Cancer |
SYNERGISTIC COMBINATION CANCER THERAPY | This case relates to anticancer protein-fatty acid complexes plus other chemotherapeutic agents as a combination for use in anticancer therapy. | Europe |
| USA | |||
| Japan |
Infections
Indication |
Patent Group |
Description |
Countries |
| Infection /Immunotherapy |
IL-1 RECEPTOR ANTAGONISTS | IL-1 receptor antagonists for the treatment of cystitis. | Australia |
| Europe (CH, DE, DK, FI, FR, NL, SE, GB) | |||
| USA | |||
| Infection /Immunotherapy |
MMP7 INHIBITORS | MMP-7 inhibitors for the treatment of cystitis. | Australia |
| Europe (CH, DE, DK, FI, FR, NL, SE, GB) | |||
| Infection /Immunotherapy | ASC / NLRP-3 | ASC or NLRP-3 proteins for the treatment of cystitis. | Europe |
| USA | |||
| Infection /Immunotherapy |
IRF7 INHIBITORS | IRF-7 inhibitors for the treatment of Enterobacteriaceae infections. | Australia |
| Europe (CH, DE, DK, FI, FR, NL, SE, GB) | |||
| USA | |||
| Infection /Immunotherapy |
NK1 ANTAGONISTS | NK1 antagonists for treating bacterial infection or management of pain caused by bacterial infections. | Europe |
| Hong Kong | |||
| USA | |||
| Infection /Immunotherapy |
POL II INHIBITORS | Inhibitors of polymerase II, which can be used for immunosuppression, anti-inflammation, and/or anti-infection. | Australia |
| Europe (CH, DE, DK, FI, FR, NL, SE, GB) | |||
| Hong Kong | |||
| India | |||
| Singapore | |||
| USA | |||
| Infection /Immunotherapy |
BLADDER PAIN | IL-1 receptor antagonists for the treatment of bladder pain. | Europe |
| USA | |||
| Australia | |||
| China | |||
| Japan | |||
| Infection /Immunotherapy |
PYELONEPHRITIS | Treatment or prevention of acute pyelonephritis and/or urosepsis. | Geat Britain, initial filing |
Tuberculosis
Indication |
Patent Group |
Description |
Countries |
| Tuberculosis |
TUBERCULOSIS TREATMENT | Bactericidal peptide Plectasin for the treatment of M. tuberculosis. | CH, DE, DK, FI, FR, NL, SE, UK, AU, CA, HK, IN, USA |